Last reviewed · How we verify
C. albicans antigen
At a glance
| Generic name | C. albicans antigen |
|---|---|
| Sponsor | South Valley University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Candin for the Treatment of Common Warts (PHASE3)
- Immunotherapy in Eyelid Viral Papilloma (PHASE2)
- Immunologic Profile of Chronically Photodamaged Skin (PHASE1)
- A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants (EARLY_PHASE1)
- Sclerotherapy and Candida Antigen in Treatment of Common Warts (NA)
- Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens (PHASE1)
- Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata (NA)
- Comparison Between Intralesional Injection of Plasma Rich Platelets and Candida Antigen in Plane Warts (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- C. albicans antigen CI brief — competitive landscape report
- C. albicans antigen updates RSS · CI watch RSS
- South Valley University portfolio CI